Sorrento Therapeutics Inc (SRNE)

[dia76ca]

I LIKE OUR CHANCES!
1. We should be hearing about Abivertinib's efficacy against Covid cytokine storm in a few weeks. We already have strong evidence of its safety and efficacy in several cancer indications. Based largely on the fact that there is no publicly accessible data on its efficacy against Covid cytokine storm I give it a 50% chance of success.

2. However we have had some early data on the dramatic effects of COVI-MSC in getting severely ill Covid patients out of the hospital within days of treatment. I give COVI-MSC at least an 80% chance of approval.

3. Similarly we have seen COVIDROPS advance in the clinic in several countries with remarkable speed. Surely this is because of solid success in phase one trials. Again I would give COVIDROPS an 80% chance of approval.

4. Meanwhile COVISTIX EUA approval in Mexico and the initial 25 million test shipment is only the beginning. I expect substantial sales in the coming weeks and EUA's in several more countries in the next few weeks.

5. Abivertinib, COVI-MSC, COVIDROPS and COVISTIX are each potential multi-billion dollar technologies. And they are only the beginning. There are more tests and drugs in the pipeline ... some with even greater potential!
I LIKE OUR CHANCES!